Topic: Research on the Progress of Chemotherapy Resistance in Triple-Negative Breast Cancer

Triple-negative breast cancer remains a significant global health challenge, with drug resistance posing a formidable obstacle to effective treatments. This Special Issue aims to explore the intricate landscape of drug resistance in triple-negative breast cancer, focusing on cutting-edge research into genetic, molecular, and metabolic mechanisms. It provides a platform for researchers to share breakthroughs, present novel hypotheses, and offer critical analyses that propel the field forward. By fostering a deeper understanding of drug (and potentially radiation) resistance, this collection aspires to inspire the development of transformative therapeutic strategies that improve patient outcomes and quality of life. 

The topics covered include, but are not limited to:

1. The molecular and metabolic pathways that enable tumor cells to evade chemotherapy-induced cytotoxicity;

2. Mechanisms underlying resistance to immune checkpoint inhibitors and other immunotherapies in triple-negative breast cancer;

3. Resistance mechanisms in triple-negative breast cancer patients treated with antibody-drug conjugates;

4. Tumor heterogeneity and emergence of resistant clones: their impact on the therapeutic response in breast cancer patients;

 etc.